NCT01302392CompletedPhase 3
A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Amgen
- Enrollment
- 315
- Primary Endpoint
- Overall Survival
Study Overview
Brief Summary
This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for subjects with multiple myeloma who have received all available approved treatment options and may therefore be considered candidates for palliative care.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Multiple myeloma
- •Measurable disease based on central laboratory values, as defined by one or both of the following criteria (assessed within 21 days prior to randomization):
- •Serum M-protein
- •Serum protein electrophoresis (SPEP): ≥ 0.5 g/dL
- •For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA): > 750 mg/dL (0.75 g/dL)
- •Urine Bence Jones protein: ≥ 200 mg/24 h
- •Responsive (defined as a 25% or greater decrease in M-protein or total protein) to at least one line of prior therapy
- •Relapsed multiple myeloma, defined as disease progression while on or after at least 1 prior treatment regimen
- •Refractory multiple myeloma, defined as meeting one or more of the following:
- •Nonresponsive to most recent therapy (eg, stable disease only, or progressive disease while on treatment)
- •Disease progression within 60 days of discontinuation from most recent therapy
- •Received 3 or more prior therapeutic regimens for multiple myeloma
- •Adequate prior treatment with bortezomib (if less than 4 complete cycles, the reason for discontinuation must be reviewed by the Medical Monitor and the reason documented)
- •Prior treatment with an immunomodulatory agent (lenalidomide, if available, and/or thalidomide)
- •Prior treatment with an alkylating agent (standard or high-dose)
- •Prior treatment with a corticosteroid
- •Criterion no longer applicable (with Amendment 2, Criterion 11, the requirement of "prior treatment with an anthracycline unless not clinically indicated" is removed.)
- •Age ≥ 18 years
- •Life expectancy of at least 1 month
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Adequate hepatic function, with serum alanine aminotransferase (ALT) < 4 times the upper limit of normal and serum bilirubin < 2.5 mg/dL (42.5 µmol/L). Patients with total bilirubin ≥ 2.5 mg/dL may enrol if their serum direct bilirubin is < 2.5 mg/dL.
- •Total white blood cell (WBC) count ≥ 1.5 × 10^9/L and absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L (use of colony-stimulating factors to achieve these counts is allowed)
- •Hemoglobin ≥ 7.5 g/dL (75 g/L)
- •Use of erythropoietic stimulating factors is allowed:
- •For all patients who receive a red blood cell (RBC) transfusion within 28 days of obtaining the Screening hemoglobin value. The following information must be provided for the Medical Monitor's review for assessment for eligibility:
- •Pre-transfusion hemoglobin (Hb)
- •Number of RBC units administered
- •Use of erythropoietic stimulating factors
- •Platelet count ≥ 30 × 10^9/L
- •There is no restriction on platelet transfusions or thrombopoietic growth factor before or during the screening period
- •For all patients who receive a platelet transfusion within 7 days of obtaining the Screening platelet value, the following information must be provided for the Medical Monitor's review for assessment of eligibility
- •Pre-transfusion platelet count
- •Number of platelet units administered
- •Use of thrombopoietic growth factors
- •Creatinine clearance (CrCl) ≥ 15 mL/minute (either measured or calculated using a standard formula such as Cockcroft and Gault) and dialysis-independent
- •Written informed consent in accordance with regulatory guidelines
- •Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of the first dose of study treatment and agree to use an effective method of contraception during the study and for 3 months following the last dose of study treatment. Post-menopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.
Exclusion Criteria
- •Waldenström's macroglobulinemia or IgM myeloma
- •Refractory to all prior therapies
- •Disease measurable only by serum free light chain assay (SFLC)
- •POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- •Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)
- •Prior carfilzomib treatment
- •Chemotherapy (approved or investigational) within 14 days prior to randomization
- •Immunotherapy or antibody therapy within 28 days prior to randomization
- •Corticosteroid therapy at a dose equivalent to dexamethasone > 4 mg/day within 14 days prior to randomization
- •Radiotherapy within 7 days prior to randomization
- •Major surgery within 21 days prior to randomization
- •Congestive heart failure (NYHA Class III or IV) or symptomatic cardiac ischemia, conduction system abnormalities uncontrolled by conventional intervention (conduction abnormalities not clinically warranting intervention are allowed)
- •Myocardial infarction in the previous 3 months
- •Acute active infection requiring systemic treatment (antibiotics, antivirals, or antifungals) within 14 days prior to randomization
- •Known human immunodeficiency virus seropositivity
- •Active hepatitis A, B, or C infection
- •Other malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix, vulva, or breast; c) prostate cancer of Gleason Score 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder, carcinoma in situ of the breast, or benign tumors of the adrenal or pancreas
- •Significant neuropathy (Grades 3-4, or Grade 2 with pain) at the time of randomization
- •Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent
- •Pregnant or lactating females
- •Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity or known history of allergy to carfilzomib, Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) all anticoagulation and antiplatelet options, antiviral drugs; or intolerance to hydration due to preexisting pulmonary or cardiac impairment
Arms & Interventions
Best Supportive Care
Active Comparator
Intervention: Best Supportive Care (Drug)
Carfilzomib
Experimental
Intervention: Carfilzomib (Drug)
Outcomes
Primary Outcomes
Overall Survival
Time Frame: From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.
Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at date when the subject is last known alive or the data cutoff date, whichever occurs earlier.
Secondary Outcomes
- Progression-free Survival(From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.)
- Overall Response(From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.)
- Duration of Response(From the time achieving response through the final analysis data cutoff with longest follow-up time of approximately 29 months.)
- Clinical Benefit Response(From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.)
- Duration of Clinical Benefit(From time of achieving clinical benefit through the final analysis data cutoff with longest follow-up time of approximately 30 months.)
- Disease Control(From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.)
- Duration of Disease Control(From time of achieving disease control through the final analysis data cutoff with longest follow-up time of approximately 31 months.)
Investigators
Similar Trials
Active, not recruiting
Phase 3
Multicenter Clinical Trial Comparing Treatment with Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control with Hyaluronic Acid in Patients with Knee Osteoarthritis.Knee OsteoarthritisNCT05086939Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León124
Active, not recruiting
Phase 3
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
Completed
Phase 3
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsMultiple MyelomaNCT01091831Fondazione EMN Italy Onlus389
Recruiting
Phase 3
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)Head and Neck Squamous Cell CarcinomasNCT05582265Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University537
Completed
Phase 3
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Relapsed Small Cell Lung CancerNCT05153239PharmaMar705